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http://dx.doi.org/10.1016/j.kjms.201Abstract Phthalatesdsubstances used in the manufacture of plasticsdare considered as
possible human carcinogens and tumor-promoting agents. The worldwide annual production
of plastics surpassed 300 million tons in 2010. Plastics are an indispensable material in modern
society, and many products manufactured from plastics are a boon to public health; however,
plastics also pose health risks. Animal studies have indicated that phthalates are carcinogenic,
but human epidemiological data confirming this carcinogenicity in humans are limited. The
activation of peroxisome proliferator-activated receptor a (PPARa), which has been observed
in rodent carcinogenesis, has not been observed in humans. Here, we review the hypothesis
that the aryl hydrocarbon receptor (AhR) and its downstream signaling cascade promote
phthalate-induced tumorigenesis.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.Introduction
Plastics are ubiquitous in modern life, public health, and
medicine. Phthalates are a group of chemicals that are used
as plasticizers to increase the flexibility and durability of
various materials. Depending on the alkyl chain, phthalates
have different properties and can be used in diverse appli-
cations. The long-chain phthalates, such as di(2-ethylhexyl)huan First Road, Kaohsiung
m (E.-M. Tsai).
vier Taiwan LLC. All rights reserv
2.05.006phthalate (DEHP), diisononyl phthalate (DINP), diisodecyl
phthalate (DIDP), and di(2-propylheptyl) phthalate (DPHP),
are primarily used in polyvinylchloride (PVC) polymers and
plastisol applications. Short-chain phthalates, such as
dimethyl phthalate (DMP), diethyl phthalate (DEP), butyl
benzyl phthalate (BBP), and di-butyl phthalate (DBP), are
often used in non-PVC products such as personal-care
products, paints, adhesives, and enteric-coated tablets [1].
Phthalates are easily released from plastics into the
environment via direct release, migration, evaporation,
leaching, and abrasion [1]. Analytical surveys of the pres-
ence of phthalate ester metabolites in urine, serum, and
other body fluids have confirmed the ubiquitous nature ofed.
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Phthalate-induced tumorigenesis mechanism S23exposure to multiple phthalates [2e8]. Diet is the most
important source of human exposure to phthalates, but
inhalation and dermal exposure are also relevant. The
highest levels of exposure (in individuals) occur via the use
of DEHP in medical plastics [9,10]. The potential for
adverse health effects due to phthalate exposure in humans
is a real concern. Most phthalates demonstrate low acute
toxicity, but research indicates that the reproductive
system is particularly susceptible to these compounds.
Phthalate esters may be associated with abnormal sexual
development and birth defects in humans [11e17].
Phthalates such as DEHP and BBP are believed to be
possible human carcinogens based on evidence of their
carcinogenicity that has been obtained in experimental
animal studies (Table 1) [18e28]. Initiation/promotion
studies in mice suggest that DEHP may promote liver
tumorigenesis [29]. Phthalates are known hepatocarcino-
genic peroxisome proliferators in rodents [30], and the
activation of peroxisome proliferator-activated receptor
a (PPARa) has been proposed as a mechanism of hep-
atocarcinogenesis. However, DEHP can cause liver tumors
in PPARa-null mice, suggesting that PPARa activation is not
essential to DEHP-induced hepatocarcinogenesis [31].
Furthermore, based on the hypothesis that humans are less
sensitive than rodents to PPARa, several reviews have
concluded that rodent hepatocarcinogenesis caused by
PPARa agonists is species-specific and not relevant to
human health [32,33]. This article focuses on the PPARa-
independent aspects of the tumor-initiating and -promoting
abilities of phthalates in humans.ci
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phthalates
There are limited epidemiological studies linking phthalate
exposure and cancer risk in humans. However, the carcino-
genicity of phthalates in humans seems to be beyond
dispute. The carcinogenicity of phthalates was first reported
in 1990 in a cohort study on 2031 Swedish PVC-processing
workers that suggested exposure to vinyl chloride signifi-
cantly increases total cancer morbidity and respiratory
cancer morbidity [34]. However, smoking and exposure to
other phthalates were not included as confounders. A nes-
ted case-control study [35] of plastics workers in the USA
showed a significantly increased risk of pancreatic cancer;
however, the limitations of this study include the exposure
assessment method, the small number of exposed case
subjects, and the exclusion of potential confounders.
A recent epidemiological investigation in Mexico repor-
ted a positive association between urinary concentrations
of diethyl phthalate and the risk of developing breast
cancer [36]. Studies in the USA and Taiwan both reported
increased risk of endometriosis and leiomyomata that were
associated with exposure to urinary monobutyl phthalate
and mono(2-ethylhexyl) phthalate [37,38].T
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Orally administered DEHP causes hepatocellular adenoma
and/or carcinoma in mice and rats of both sexes, and
S24 Y.-C. Wang et al.significant dose-related trends in tumor incidence have
been observed [39]. BBP is most likely carcinogenic, as
administered BBP increases tumor incidence in female
F344/N rats [18,19,40]. Several studies have suggested
that dietary exposure to DEHP causes liver tumors [30],
Leydig cell tumors [41], and benign pancreatic tumors in
rats [42]. Other phthalates, such as diisononyl phthalate
[43] and diisodecyl phthalate [44], have also been repor-
ted to increase tumor risk. The European Chemicals
Bureau [45] reviewed several in vivo tumor initiation/
promotion experiments that were performed on rats and
mice. The data suggest that DEHP is a tumor-promoting
agent, but not a tumor-initiating agent, in the liver.
Genotoxicity assays
Salmonella mutation assays have indicated that BBP and
DEHP are not direct mutagens [18,19]. However, phthalates
have exhibited mutagenic activity on several other assays
(Table 1). These results suggested that DEHP, BBP, DMP, and
DBP are potential mutagens.
Cellular studies
Numerous studies on the carcinogenicity and mechanisms
of carcinogenicity of phthalates have been performed
in vitro. Several mammalian cell transformation assays
have indicated that phthalates demonstrate positive
transforming potential (Table 2). Other studies provide
evidence that DEHP acts as an initiator and promoter of
tumors [46]. BBP increases the invasion capacity of MCF-10F
cells in a dose-response manner [47]. DEHP reduces
apoptosis in Syrian hamster embryo cells by increasing bcl-2
and decreasing c-myc [48]. These effects may initiate from
following pathways.
Peroxisome proliferator-activated receptor a
The ability of peroxisome proliferator-activated receptor
a (PPARa) activation to cause cancer in humans has beenTable 2 Summary of genetic toxicological information on phth
Testing method Cell and animal sp
Reverse mutation test Salmonella Typhim
E. coli
Chromosome aberration test Fetal Syrian hams
Chinese hamster o
Mouse bone marro
Sister chromatin exchange test Chinese hamster o
Genetic mutation test Mouse lymphoma
Sex-linked recessive lethal test Drosophila melanoquestioned [32,33]. Many PPARa-activating compounds
have been reported to exhibit diverse effects in addition to
peroxisome proliferation, including genotoxicity, epige-
netic alterations, and oxidative stress. Ito et al. [31]
reported that DEHP tumorigenesis in mice is not PPARa-
dependent. Takashima et al. [49] suggested that DEHP
induces hepatocarcinogenesis via the suppression of
Gadd45a-regulated G2/M arrest and caspase 3-dependent
apoptosis in PPARa-null mice, but not in wild-type mice.
To understand if the human PPARa influenced by DEHP,
another study introduced human PPARa gene into PPARa-
null mice [50]. This mice produces human PPARa, but not
mouse PPARa. The human PPARa protein can be induced by
PPAR agonists in hPPARaPAC mice, similar to the situation in
wild-type mice. However, treatment of hPPARaPAC mice
with a PPAR agonist did not cause significant hepatomegaly
or hepatocyte proliferation, which are typically found in
wild-type mice. This result suggests that the resistance to
hepatocellular proliferation observed in hPPARaTetOff mice
is not due to the lack of PPAR receptor expression in tissues
other than the liver, implying that PPARa agonists may not
be carcinogenic in humans.
Aryl hydrocarbon receptor (AhR)
The aryl hydrocarbon receptor (AhR) is a basic helix-loop-
helix transcription factor that is activated by halogenated
aromatic hydrocarbons, polycyclic aromatic hydrocarbons,
and endogenous compounds. Phthalates can affect AhR
function in a dose-dependent manner [51]. Upon ligand
activation, AhR dissociates from heat shock protein 90 [52].
Dissociated AhR translocates to the nucleus and dimerizes
with the AhR nuclear translocator (Arnt) [53]. The AhR/
ARNT heterodimer translocates into the nucleus and binds to
AhR-responsive elements that are upstream of the target
genes that regulate gene expression, such as cytochrome
P450 (CYP) gene activation and immunoglobulin suppression
[54]. Experimental evidence suggests that AhR plays an
important role in cell proliferation, differentiation, and
hepatic and immune system homeostasis, as well as in tumor
development [55] and mammary gland tumorigenesis [56].alates.
ecies used Results References
urium BBP(-)
DEHP(-)
DINP(-)
[18e24]
DEHP(-) [22]
ter cells DEHP(þ) [25]
vary cells BBP(-)
DEHP(þ)
[26,27]
w cells BBP(þ) [19,20]
vary cells BBP(-) [19,26]
cell BBP(-)
DIDP(-)
DINP(-)
DMP(þ)
DBP(þ)
[28]
gaster BBP(-) [19]
Phthalate-induced tumorigenesis mechanism S25The best-characterized factor through which AhR
contributes to carcinogenesis is CYP1b1. The tumor-specific
transcriptional activation of CYP1b1 has been found in
various types of human cancers, including cancers of the
breast, colon, lung, esophagus, skin, lymph node, brain,
and testes [57]. CYP1b1 encodes a monooxygenase that is
capable of metabolizing xenobiotics, such as polycyclic
aromatic hydrocarbons and endogenous estrogen [58].
CYP1b1 specifically hydroxylates estradiol to 4-hydroxy
estradiol (4-OHE2), which is a more potent carcinogen
[59]. 4-OHE2 is further oxidized to estrogen-3,4-
semiquinone and quinine, which is accompanied by the
generation of reactive oxygen species (ROS) and DNA
adducts [60]. DNA adduct formation is the key intermediate
that links mutations to critical oncogenes and tumor
suppressor genes during cancer development [61,62]. In
addition, CYP1b1 promotes endometrial carcinogenesis by
targeting multiple pathways, including the cell cycle,
apoptosis, and cell adhesion, by regulating cyclin E1, S-
phase kinase-associated protein 2, mini-chromosome
maintenance complex component 4, RAD51, p27(Kip1),
and cyclin E-binding protein [63].
In addition to the classic AhR genomic pathway
described above, several nongenomic AhR pathways of
activation have been reported in association with mito-
genic responses, such as increased human epidermal
growth factor receptor 2 (HER2/neu), v-myc myelocyto-
matosis viral oncogene homolog (c-myc), FBJ murine
osteosarcoma viral oncogene homolog (c-fos), jun proto-
oncogene (c-jun), Ha-ras Harvey rat sarcoma viral onco-
gene homolog (Ha-ras) [64e66], cyclin-dependent kinase 4
(CDK4) [67], and nuclear factor kappa-B (NF-kB) [68e70].
C-Myc expression induces telomerase activity through AhR
signaling and/or ER-independent activities [71]. High levels
of telomerase activity have been found in several malig-
nant tumors [72,73]. These results suggest that AhR
induced c-Myc expression may be an important mediator of
phthalate-induced oncogenesis. Our previous results also
suggest that phthalates trigger the downstream cyclic AMP-
protein kinase A (PKA)-CAMP responsive element binding
protein 1 (CREB1) signaling cascade in order to increase
the expression of histone deacetylase 6 (HDAC6) [74].
HDAC6 further transcriptionally activates c-Myc through b-
catenin-LEF1/TCF4 in human estrogen receptor-negative
breast cancer tumor cells. The effects of AhR-HDAC6-c-
Myc activation include increased cell proliferation, migra-
tion, and invasion activities in vitro and increased tumor
growth in vivo [74].
Another nongenomic AhR-activated factor that contrib-
utes to carcinogenesis is cyclooxygenase-2 (Cox-2) [75e77].
The upregulation of COX-2 and elevated prostaglandin E2
(PGE2) levels are involved in breast carcinogenesis [78,79].
The COX-2/PGE2 pathway also plays key roles in colorectal
tumorigenesis [80]. The overexpression of COX-2 increases
tumor angiogenesis and cellular proliferation, thereby
promoting tumor development and invasion [80,81]. COX-2
was found to have similar pro-invasion, pro-angiogenesis,
and anti-apoptosis activities in breast tumorigenesis [82].
Identification of the additional nongenomic pathways that
are activated by AhR or cross-talk between estrogen
receptor (ERa and ERb) signals and other factors involved in
tumorigenesis requires further study.However, the increased incidence of prostate tumors in
AhR-null mice compared with AhR wild-type mice [83]
suggests that AhR has both oncogenic and tumor-
suppressing properties. The tumor-suppressing effects of
AhR have also been reported in liver tumorigenesis [84].
These data suggest that the AhR functions as a tumor
suppressor gene in the absence of xenobiotic ligands, and
its activation by phthalate is associated with cancer
progression. Further studies are needed to clarify the roles
of AhR both with and without xenobiotic ligands.Conclusions and future issues
Recently reported findings have demonstrated that the
carcinogenicity of phthalates via the PPARa pathway may
be specific to rodents and irrelevant to human health.
However, further studies have suggested that phthalates
promote and induce tumorigenesis in a variety of cell types
through AhR-mediated genomic and nongenomic pathways.
This appears to be dependent on the presence or absence
of phthalates, but the specific mechanisms that are acti-
vated by each type of phthalate, or the combined effects of
different phthalates, are still unknown. As a result,
tumorigenesis induced by phthalate exposure and mediated
by AhR is an emerging public health concern that warrants
further investigation.References
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